Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05322070 · ClinicalTrials.gov registry record · Phase 4

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

A Phase 4 study of Uveitis, Posterior, sponsored by Alimera Sciences.

Active
Registry status
Phase 4
Development phase
125
Enrollment target
20
Study locations

NCT05322070 is a Phase 4 study of Uveitis, Posterior that is active but no longer recruiting, run by Alimera Sciences. The registered enrollment target is 125 participants, below the 139-participant average among 6 other Uveitis, Posterior trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05322070, a Phase 4 study of Uveitis, Posterior, is active but no longer recruiting, sponsored by Alimera Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
125 participants
Enrollment target
20
Study locations

Study Summary

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

Conditions Studied

Interventions

  • DRUG Fluocinolone Acetonide Intravitreal Implant 0.18 mg

Study Locations (20)

California

  • Retina Consultants of Orange County - Fullerton
  • Macula and Retina Institute - Glendale
  • California Eye Specialists Medical Group - Pasadena
  • Retinal Consultants Medical Group - Sacramento

Florida

  • Advanced Research - Coral Springs
  • Retina Specialists of Tampa - Wesley Chapel

Illinois

  • Retinal Vitreal Consultants Ltd. - Chicago
  • Illinois Retina Associates, S.C. - Oak Park

Massachusetts

  • Opthalmic Consultants of Boston - Boston
  • Massachusets Eye Research and Surgery Institution - Waltham

Colorado

  • Retina Associates of Colorado - Lakewood

Georgia

  • Marietta Eye Clinic - Marietta

Maryland

  • Cumberland Valley Retina Consultants - Hagerstown

Michigan

  • Foundation for Vision Research - Grand Rapids

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2022-06-06
Est. Completion 2025-11
Phase Phase 4

Sponsor

Alimera Sciences

8 total trials

What the Registry Record Tells You About NCT05322070

The ClinicalTrials.gov registry entry for NCT05322070 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 6 other Uveitis, Posterior trials with a reported enrollment target (10% lower). The listed sponsor is Alimera Sciences, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Uveitis, Posterior appearing as the primary indexed condition, and to 1 intervention - of which Fluocinolone Acetonide Intravitreal Implant 0.18 mg is the first listed.

NCT05322070 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05322070 about?

NCT05322070 is a clinical study titled "Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis". A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

What is the current status of trial NCT05322070?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2022-06-06. Estimated completion is 2025-11.

What conditions does trial NCT05322070 study?

This clinical trial studies the following conditions: Uveitis, Posterior.

What interventions are being tested in trial NCT05322070?

The interventions under investigation include: Fluocinolone Acetonide Intravitreal Implant 0.18 mg (DRUG).

Who is sponsoring clinical trial NCT05322070?

This trial is sponsored by Alimera Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05322070 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uveitis, Posterior

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.